Liver-tissue risk
You want to never meet it. It sits here so the earlier nodes read as what they are: the place where the outcome is still open.
In depth
Where unchecked fibrosis is heading. Liver stiffness predicts it before it arrives — in fatty liver disease, a reading above 9.3 kPa carried a hazard ratio of 13.8 for developing it, independent of age, platelets and enzymes.
What drives it
Tissue scarring increases it.
The number that answers 'why does stiffness matter', and it is measured in fatty liver disease specifically. PMC8472221, a liver-stiffness-based HCC risk model in NAFLD (defined as CAP >=238 dB/m), median follow-up 64.6 months: 'In multivariate analysis, AGE >=60 years (HR = 9.1), platelet count <150 (HR = 3.7), and liver stiffness >=9.3 kPa (HR = 13.8) were independent predictors.' AUC for predicting HCC at 2, 3 and 5 years: 0.948, 0.947, 0.939. A dose ladder in a second population (PMID 38061410, HCV cirrhosis post-SVR): 'The adjusted annual risk of HCC was 2.03% with LSM <10 kPa, 2.48% at 10-14.9 (aHR 1.71), 3.22% at 15-19.9, 5.07% at 20-24.9 (aHR 2.55), and 5.44% at >=25 kPa (aHR 3.03; P <.0001).' And a floor: 'patients with LSM <5 kPa in the absence of diabetes had a low risk of HCC in which surveillance could be discontinued.' Scope, and it is the whole point for this blend: stiffness is a measurement of fibrosis, not a separate biology - which is why NO 'stiffness' node was built. And the Russian-language source found A 4,520-person NHANES elastography analysis in which coffee was associated with lower liver stiffness but not steatosis - the two readings come off the same machine and can move independently. Nothing on this blend has been shown to lower liver stiffness in a person. PMID 38061410 · PMC8472221
Liver scarring increases it.
The terminal edge. PMC11675116, a prospective study of 299 cirrhotic patients with liver and spleen elastography by a single blinded operator: 'LSM has shown high accuracy for diagnosing liver cirrhosis, as well as for predicting decompensation and HCC development'; median LSM 25.7 kPa, median spleen stiffness 44.6 kPa. And the direction is reversible in at least one setting: 'liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes' (Piedade et al., Sci Rep 2021;11:11681), and after resection 'achieving LSM <=8 kPa suggested a reduced risk of late recurrence (HR 0.519; 95% CI 0.307-0.877; p = 0.014)'. Stiffness falling tracks risk falling. Both regression findings ARE in viral hepatitis treated with ANTIVIRALS OR surgery, not in metabolic OR alcoholic fatty liver, and not with any supplement. The Russian-language source also records that HCC risk persists after abstinence once cirrhosis exists. PMC11675116
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.